previous slide

Loading ...

Loading ...
next slide
Dr. Jeffrey Heier

Active Studies and Enrolling Patients:

Age-Related Macular Degeneration (AMD)

APL2-103 – A Phase Ib Multi-Center, Open Label, Single Arm Study to Evaluate the Safety of Intravitreal APL-2 Therapy in Patients Diagnosed with GA Secondary to AMD  [link not yet available]

ARCHWAY - A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular AMD (GR40548)

DERBY - A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with GA Secondary to AMD (APL2-303)

HMR1002 - A Phase 1 Proof of Concept Trial Evaluating Intravitreal AAVCAGsCD59 for the Treatment of Wet AMD

MERLIN – A Multicenter, Randomized, Double-Masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6mg Q4 Weeks Compared to Aflibercept 2mg Q4 Weeks in Patients with Neovascular AMD with Persistent Retina Fluid

PANDA - A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular AMD (KHB-1801)



Diabetic Eye Disease

YOSEMITE - A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with DME (GR40349)

KESTRAL -  A randomized, double masked, multicenter, phase III study assessing the efficacy and safety of Brolucizumab versus Aflibercept in adult patients with visual impairment due to DME (RTH258B2301)

THR-149-001 - A Phase 1, open-label, multicenter, dose escalation study to evaluate the safety of a single intravitreal injection of THR-149 for the treatment of diabetic macular edema (DME)

KVD001-201 – A Randomized Sham-Controlled Double-Masked Phase 2a Study of the Efficacy, Safety and Tolerability of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects with Center-Involving Diabetic Macular Edema (ciDME) Who Have Had Prior Anti-Vascular Endothelial Growth Factor (VEGF) Treatment


Retina Venous Occlusive Disease

TOPAZ - Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

Stargardt Disease

OPH2005 – A Phase 2b Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease


Active Studies No Longer Enrolling Patients:

Age-Related Macular Degeneration 

HMR-1001 - A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2CAGsCD59 in Patients with Advanced Non-Exudative (Dry) Age-Related Macular Degeneration with Geographic Atrophy

RGX-314-001 - A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy with RGX-314 in Subjects with Neovascular AMD (nAMD)

OPH2003 – A Phase 2B Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Zimura (Anti-Complement Factor 5 Aptamer) in Subjects with Geographer Atrophy (GA) Secondary to Dry Age-Related Macular

PRO-CON VGFTe-AMD-1507- A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) versus Sham as PROphylaxis against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes.

PRELUDE - CNTO2476MDG2002 - A Phase 2b, multicenter, double-masked, randomized study evaluating the safety and clinical response of sub-retinal administration of CNTO 2476 in subjects with visual acuity impairment associated with Geographic Atrophy Secondary to Age Related Macular Degeneration

Diabetic Eye Disease 

Time2B / AKB-9778-CI-5001 – A Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy

PANORAMA – VGFTe-OD-1411 – A Phase III, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy


Back to research home page

Find Our Doctors

Request an Appointment
New & Established Patients
* required field   *   *   *   *     *     * Include Preferred Day & Time

Refill a Prescription
Place your order 24/7. OCB utilizes a secure portal called Patient Gateway for prescription refills

Newsletter OCB Summer Newsletter Download ...
View past eNewsletters
Sign Up for OCB's eNewsletter * *
About OCB
OCB Boston
50 Staniford Street, Suite 600
Boston, MA 02114

PH 1.800.635.0489
FAX 1.617.723.7028
Quick Links
Stay Connected
@ OCB All Rights Reserved | Careers | Employee Login
Site Development: Linking Shores Consulting Inc.

Loading ...